In: NEOPLASMA, vol. 64, no. 4
O. Fiala - P. Hosek - M. Pešek - J. Finek - J. Racek - T. Buchler - A. Poprach - K. Hejduk - R. Chloupkova - O. Sorejs - M. Ecksteinova - M. Vitovec - K. Cizkova - R. Kucera - O. Topolcan
Detaily:
Rok, strany: 2017, 605 - 610
O článku:
Pemetrexed is an intravenously administered antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC). It has been previously demonstrated that the superiority of pemetrexed is limited to patients with non-squamous histology. Aside from the non-squamous histology, there is still no available molecular biomarker predicting treatment efficacy of pemetrexed-based chemotherapy. The aim of our retrospective study was to evaluate the association of baseline serum levels of C-reactive protein (CRP) with outcomes in a large cohort of patients with non-squamous NSCLC treated with pemetrexed. Clinical data of 325 patients were analysed. Serum samples were collected within one week before the initiation of treatment. The median progression-free (PFS) and overall survival (OS) for patients with high CRP was 2.1 and 9.5 compared to 4.2 and 20.5 months for those with normal CRP (p=0.002 and p<0.001, respectively). The multivariable Cox proportional hazards model revealed that serum CRP (HR=1.46, p=0.002) was significantly associated with PFS and also with OS (HR=1.95, p<0.001). In conclusion, the study results suggest that pretreatment serum CRP is associated with poor outcome of non-squamous NSCLC patients treated with pemetrexed. Keywords: C-reactive protein, lung cancer, NSCLC, chemotherapy, pemetrexed, prognosis
Ako citovať:
ISO 690:
Fiala, O., Hosek, P., Pešek, M., Finek, J., Racek, J., Buchler, T., Poprach, A., Hejduk, K., Chloupkova, R., Sorejs, O., Ecksteinova, M., Vitovec, M., Cizkova, K., Kucera, R., Topolcan, O. 2017. Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed. In NEOPLASMA, vol. 64, no.4, pp. 605-610. 0028-2685.
APA:
Fiala, O., Hosek, P., Pešek, M., Finek, J., Racek, J., Buchler, T., Poprach, A., Hejduk, K., Chloupkova, R., Sorejs, O., Ecksteinova, M., Vitovec, M., Cizkova, K., Kucera, R., Topolcan, O. (2017). Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed. NEOPLASMA, 64(4), 605-610. 0028-2685.